Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$0.41 -5.4%	$0.29	$0.22 ▼ $3.23	$19.04M	0.52	4.00 million shs	2.64 million shs
IMMX Immix Biopharma	$2.35 -5.6%	$1.99	$1.26 ▼ $3.00	$65.51M	0.31	155,971 shs	47,717 shs
NRXP NRx Pharmaceuticals	$3.44	$2.38	$1.10 ▼ $6.01	$59.47M	1.54	413,678 shs	357,688 shs
OTLK Outlook Therapeutics	$1.82 -1.1%	$1.60	$0.87 ▼ $9.25	$61.09M	0.31	800,759 shs	302,531 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+14.52%	+62.87%	+30.93%	-87.59%
IMMX Immix Biopharma	0.00%	-0.84%	+12.44%	+42.42%	+9.81%
NRXP NRx Pharmaceuticals	0.00%	+5.20%	+43.33%	+46.38%	+1.78%
OTLK Outlook Therapeutics	0.00%	-4.21%	+8.66%	+15.92%	-75.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLRB Cellectar Biosciences	2.6643 of 5 stars	3.2	5.0	3.3	0.0	0.6
IMMX Immix Biopharma	2.6341 of 5 stars	3.5	3.0	2.6	1.7	0.6
NRXP NRx Pharmaceuticals	2.0832 of 5 stars	3.6	1.0	3.1	0.8	0.6
OTLK Outlook Therapeutics	1.4056 of 5 stars	3.4	1.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.33	Hold	$12.50	2,925.17% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	197.87% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	728.49% Upside
OTLK Outlook Therapeutics	2.80	Moderate Buy	$9.60	427.47% Upside

Current Analyst Ratings Breakdown

Latest CLRB, IMMX, OTLK, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	OTLK Outlook Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/20/2025	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/14/2025	CLRB Cellectar Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	($0.96) per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.81 per share	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.38) per share	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.57) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$42.77M	-$0.73	N/A	N/A	N/A	N/A	N/A	-191.22%	8/11/2025 (Estimated)
IMMX Immix Biopharma	-$15.43M	-$0.70	N/A	N/A	N/A	N/A	-102.68%	-80.89%	8/11/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$30.15M	-$2.01	N/A	N/A	N/A	N/A	N/A	-449.16%	8/13/2025 (Estimated)
OTLK Outlook Therapeutics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-225.12%	8/13/2025 (Estimated)

Latest CLRB, IMMX, OTLK, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/15/2025	Q2 2025	OTLK Outlook Therapeutics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/13/2025	Q1 2025	CLRB Cellectar Biosciences	-$0.17	-$0.13	+$0.04	-$0.14	N/A	N/A
3/24/2025	Q4 2024	IMMX Immix Biopharma	-$0.25	-$0.16	+$0.09	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	1.77	1.77
IMMX Immix Biopharma	N/A	3.47	3.47
NRXP NRx Pharmaceuticals	N/A	0.20	0.20
OTLK Outlook Therapeutics	N/A	0.32	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
IMMX Immix Biopharma	11.26%
NRXP NRx Pharmaceuticals	4.27%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	5.04%
IMMX Immix Biopharma	55.40%
NRXP NRx Pharmaceuticals	19.00%
OTLK Outlook Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	46.08 million	44.38 million	Optionable
IMMX Immix Biopharma	9	27.88 million	14.06 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	12.72 million	Optionable
OTLK Outlook Therapeutics	20	33.57 million	30.48 million	Optionable

CLRB, IMMX, OTLK, and NRXP Headlines

Recent News About These Companies

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12 at 10:48 AM | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12 at 10:48 AM | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12 at 5:48 AM | bleepingcomputer.com

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

June 11, 2025 | pharmaceutical-technology.com

Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | finanznachrichten.de

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | globenewswire.com

Highlights | Outlook Planet’s C³ Summit & Awards 2025

June 7, 2025 | outlookbusiness.com

Natural Gas Price Outlook – Natural Gas Continues to See Same Resistance Level

June 7, 2025 | fxempire.com

Oilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 Moment

June 7, 2025 | msn.com

ChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New Pricing

June 7, 2025 | techrepublic.com

Outlook Therapeutics (NASDAQ:OTLK) Given New $21.00 Price Target at Ascendiant Capital Markets

June 6, 2025 | marketbeat.com

Outlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMD

June 4, 2025 | pharmabiz.com

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

June 2, 2025 | globenewswire.com

Q3 EPS Estimate for Outlook Therapeutics Boosted by Analyst

May 31, 2025 | marketbeat.com

Brookline Capital Management Forecasts OTLK FY2026 Earnings

May 30, 2025 | marketbeat.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by Analysts

May 24, 2025 | marketbeat.com

Outlook Therapeutics announces public stock offering

May 24, 2025 | investing.com

Outlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants

May 24, 2025 | nasdaq.com

Outlook Therapeutics announces proposed public offering of common stock, warrants

May 23, 2025 | msn.com

Outlook Therapeutics drops 17%, prices $13M stock offering

May 23, 2025 | msn.com

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, IMMX, OTLK, and NRXP Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$0.41 -0.02 (-5.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.35 -0.06 (-14.33%)

As of 06/13/2025 07:59 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Immix Biopharma NASDAQ:IMMX

$2.35 -0.14 (-5.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.36 +0.00 (+0.21%)

As of 06/13/2025 07:56 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

NRx Pharmaceuticals NASDAQ:NRXP

$3.44 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.44 0.00 (0.00%)

As of 06/13/2025 07:07 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Outlook Therapeutics NASDAQ:OTLK

$1.82 -0.02 (-1.09%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.82%)

As of 06/13/2025 07:07 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time